Cost and controversy are limiting use of new Alzheimer’s drug

(By Jon Hamilton for NPR)

The new Alzheimer’s drug Aduhelm isn’t reaching many patients. And doctors say reasons include its high cost, insurers’ reluctance to cover it, and lingering questions about whether it actually slows memory loss.  Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org